RDNT RadNet, Inc.
USHealthcareAs of 2026-07-09 16:00
Why RDNT matters now
RadNet, Inc. (RDNT) is a US stock in Healthcare. The latest InvestLog snapshot shows $65.94 with +0.53% on the session and $5.19B in market capitalization; recent performance reads 1-month +0.73% and YTD -24.68%.
The latest financial table shown here is Q1 2026, with revenue of $575.6M, net income of $-33.5M, and EPS of $-0.43. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.5%.
The latest indexable market news headline is "RDNT's Unit DeepHealth Expands AI Breast Suite With FDA-Cleared Tools" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $91.50; recent insider activity includes Berger Howard G filing G-Gift. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.83
P/S
1.97
EV/EBITDA
17.61
DCF Value
$-37.91
FCF Yield
-3.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
9.4%
Operating Margin
3.8%
Net Margin
-0.7%
ROE
-1.4%
ROA
-0.4%
ROIC
1.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $575.6M | $-33.5M | $-0.43 |
| Q4 2025 | $547.7M | $-597.0K | $-0.01 |
| FY 2025 | $2.04B | $-18.7M | $-0.25 |
| Q3 2025 | $522.9M | $5.4M | $0.07 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$85.00
Target (Median)
$91.50
Target Range
$65.00 - $92.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
1.39
RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures. Beyond direct patient services, the company also plays a significant role in developing and marketing specialized computerized systems for the diagnostic imaging sector, such as picture archiving communication systems (PACS) and associated support. Furthermore, RadNet is at the forefront of integrating artificial intelligence (AI) solutions, designing and deploying AI suites to augment radiologist interpretation, particularly in mammography, and extending these AI capabilities to lung and prostate cancer diagnostics. As of December 31, 2021, its operational footprint included ownership and management of 347 centers situated across seven states: Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Established in 1981, the company maintains its headquarters in Los Angeles, California.